SUSMED,Inc.

SUSMED,Inc.

TTSE:4263
354.00
JPY
-10.00
(-2.75%)
10.18BMarket Cap
Nov 06Next Earn
SUSMED,Inc.
TSE:4263
(Tokyo Stock Exchange)

Recent

price

354.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
JPY
2.24
9.03
21.58
32.35
20.52
- -
- -
Revenue per Share
-6.23
-21.69
-15.9
-3.09
-21.41
- -
- -
Basic EPS, GAAP
-5.99
-18.72
-12.12
5.02
-14.38
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
22.85
101.47
299.39
293.02
274.73
- -
258.11
Book Value per Share
22.85
101.47
299.39
292.57
274.22
- -
257.12
Tangible Book Value per Share
16
13
15
16
17
17
17
Basic Weighted Avg Shares
35
115
317
531
343
- -
- -
Sales/Revenue/Turnover
-460.7
-288.7
-72.32
-9.1
-106.54
- -
- -
Operating Margin (%)
- -
- -
2
6
6
- -
- -
Depreciation Expense
-97
-278
-233
-51
-357
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-277.81
-240.33
-73.68
-9.56
-104.33
- -
- -
Profit Margin (%)
356
1,579
4,848
4,861
4,577
- -
4,293
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
355
1,578
4,850
4,871
4,604
- -
4,338
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-28.72
-7.26
-1.04
-7.54
- -
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Mar'24
Jun'24
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
8,866
10,056
10,185

Working Capital

JPY

•

in mil. unless spec.
Mar'24
Jun'24
Dec'25
Total Current Assets
5,012
4,898
4,633
Cash, Cash Equivalents & STI
4,954
4,847
4,557
Accounts Receivable, Net
20
10
20
Inventories
- -
- -
- -
Total Current Liabilities
314
321
340
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33
232
43
35
343
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-8.79
3.29
-7.6
-8.3
-21.41
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
SUSMED, Inc. (4263.T) develops and provides sustainable medical and healthcare solutions focused on reducing environmental impact in the medical field. The company offers products including eco-friendly disposable medical supplies such as paper-based gowns, drapes, and trays; reusable sterilization containers and related accessories; and consulting services for hospital waste reduction and sustainability initiatives. SUSMED operates primarily in Japan, serving hospitals, clinics, and medical facilities with a focus on the domestic healthcare sector. Founded in 2022 and headquartered in Tokyo, Japan, SUSMED emphasizes circular economy principles in medical waste management, targeting large-scale healthcare providers seeking compliance with environmental regulations and cost efficiencies. Its product lineup features proprietary brands like the "Green Series" for single-use paper medical wearables and the "Cycle Container" system for durable sterilization and transport, complemented by digital tools for tracking waste metrics. In recent developments, SUSMED expanded its operations through a strategic partnership with major Japanese hospital chains in 2024 to pilot zero-waste programs, alongside securing a JPY 1.2 billion funding round led by healthcare-focused venture capital firms to accelerate production scaling. The company launched its next-generation biodegradable infusion sets in early 2025, marking entry into fluid management products, and reorganized its business units to include an international division targeting Southeast Asian markets. These changes position SUSMED for growth amid rising demand for ESG-compliant medical supplies in Asia.